Related Experiment Video
Updated: Mar 10, 2026
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
Extracorporeal Membrane Oxygenation in Dengue, Malaria, and Acute Chagas Disease
Leonardo A Salazar1, Cornelis M Schreuder, Jhonathan A Eslava
1From the *Department of Cardiovascular Surgery and Research Center, Fundación Cardiovascular de Colombia, Floridablanca, Colombia; †Erasmus University, Rotterdam, the Netherlands; ‡Department of Pediatric Pneumology, Fundación Cardiovascular de Colombia, Floridablanca, Colombia; §Respiratory Department, Fundación Cardiovascular de Colombia, and Respiratory Health Center, Hospital Internacional de Colombia; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; ¶Pompeu Fabra University, Barcelona, Spain; and ‖Department of Cardiology, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
Abstract:
Extracorporeal membrane oxygenation (ECMO) is widely used in acute respiratory distress syndrome (ARDS) and myocarditis. Severe vector-mediated diseases may be complicated by ARDS or myocarditis, which are both associated with a high mortality rate. We present six cases of severe dengue, malaria, and acute Chagas disease that were treated with ECMO from September 2007 to September 2015. Patients included two pediatric and four adults (aged 12-48). Survival to decannulation was 83% and to discharge was 66%. Overall, the mean duration on ECMO was 25.4 days. We conclude that ECMO treatment can be beneficial in patients with severe dengue, malaria, and acute Chagas disease, if complicated by pulmonary or cardiac complications.
